Synbio International Achieves DWAC and DRS Eligibility, Enhancing Trading Efficiency and Shareholder Access

Synbio International Inc. has been approved for DWAC and DRS processing, modernizing its trading infrastructure to enable faster electronic transfers and broader market access for investors.

NY Metrowire Staff
Technology
Synbio International Achieves DWAC and DRS Eligibility, Enhancing Trading Efficiency and Shareholder Access

Synbio International Inc. (OTC: SYIN) announced today that it has secured approval for Deposit/Withdrawal at Custodian (DWAC) and Direct Registration System (DRS) processing through its transfer agent, Pacific Stock Transfer Company. This development marks a significant step in the company's efforts to modernize its trading infrastructure and improve accessibility for both existing shareholders and prospective investors.

DWAC eligibility allows for electronic transfer of shares between broker-dealers and the company's transfer agent, eliminating the need for physical share certificates. This reduces settlement times and lowers transaction friction, enabling more efficient trading in the open market. In parallel, DRS enables shareholders to hold their shares directly on the company's books in electronic form, without requiring a physical certificate or intermediary custody. This provides investors with greater control, enhanced ownership security, and simplified transferability.

“Achieving DWAC and DRS eligibility is a foundational step in strengthening Synbio’s capital markets platform,” said Claudio Solitario, CEO of Synbio International. “As we continue to advance our strategic initiatives, including our planned financing activities and partnership developments, it is critical that our stock is easily accessible and efficiently tradable for the investment community. This positions the Company to move quickly as we execute on a number of near-term initiatives currently in progress.”

The announcement comes as Synbio continues its transition toward a more investor-ready, execution-focused public company platform, with multiple near-term capital markets and operational catalysts expected. The company, which focuses on clinically validated AI-driven medical diagnostics, aims to bridge the gap between wellness and medicine through strategic partnerships and research collaborations.

Investors and shareholders can find more information about Synbio International's initiatives on the company's website at www.synbiointl.com. This development is expected to facilitate smoother trading and potentially attract a broader investor base as the company pursues its growth strategy.

Blockchain Registration

QR Code for Blockchain Registration